Annual CFF
$66.77 M
+$65.72 M+6250.88%
31 December 2023
Summary:
SAB Biotherapeutics annual cash flow from financing activities is currently $66.77 million, with the most recent change of +$65.72 million (+6250.88%) on 31 December 2023. During the last 3 years, it has risen by +$57.79 million (+643.39%). SABS annual CFF is now at all-time high.SABS Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
-$674.10 K
-$353.10 K-110.00%
30 September 2024
Summary:
SAB Biotherapeutics quarterly cash flow from financing activities is currently -$674.10 thousand, with the most recent change of -$353.10 thousand (-110.00%) on 30 September 2024. Over the past year, it has dropped by -$533.80 thousand (-380.47%). SABS quarterly CFF is now -101.00% below its all-time high of $67.64 million, reached on 31 December 2023.SABS Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$66.25 M
-$533.80 K-0.80%
30 September 2024
Summary:
SAB Biotherapeutics TTM cash flow from financing activities is currently $66.25 million, with the most recent change of -$533.80 thousand (-0.80%) on 30 September 2024. Over the past year, it has increased by +$58.72 million (+780.53%). SABS TTM CFF is now -0.80% below its all-time high of $66.78 million, reached on 30 June 2024.SABS TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SABS Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6250.9% | -380.5% | +780.5% |
| 3 y3 years | +643.4% | -1216.6% | +10000.0% |
| 5 y5 years | - | - | - |
SABS Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +6250.9% | -101.0% | +89.3% | -0.8% | >+9999.0% |
| 5 y | 5 years | at high | +6250.9% | -101.0% | +89.3% | -0.8% | >+9999.0% |
| alltime | all time | at high | +6250.9% | -101.0% | +89.3% | -0.8% | >+9999.0% |
SAB Biotherapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$674.10 K(+110.0%) | $66.25 M(-0.8%) |
| June 2024 | - | -$321.00 K(-18.6%) | $66.78 M(+0.1%) |
| Mar 2024 | - | -$394.40 K(-100.6%) | $66.74 M(-0.1%) |
| Dec 2023 | $66.77 M(+6250.9%) | $67.64 M(<-9900.0%) | $66.77 M(+787.5%) |
| Sept 2023 | - | -$140.30 K(-61.4%) | $7.52 M(+2.0%) |
| June 2023 | - | -$363.80 K(+1.1%) | $7.38 M(+5.2%) |
| Mar 2023 | - | -$359.80 K(-104.3%) | $7.01 M(+566.6%) |
| Dec 2022 | $1.05 M | $8.39 M(-3021.5%) | $1.05 M(-96.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | -$287.10 K(-60.7%) | $28.70 M(-0.8%) |
| June 2022 | - | -$731.00 K(-88.4%) | $28.93 M(-2.3%) |
| Mar 2022 | - | -$6.32 M(-117.5%) | $29.62 M(-17.5%) |
| Dec 2021 | $35.89 M(+299.6%) | $36.03 M(<-9900.0%) | $35.89 M(<-9900.0%) |
| Sept 2021 | - | -$51.20 K(+10.8%) | -$142.90 K(+55.8%) |
| June 2021 | - | -$46.20 K(+1.5%) | -$91.70 K(+101.5%) |
| Mar 2021 | - | -$45.50 K | -$45.50 K |
| Dec 2020 | $8.98 M(+144.0%) | - | - |
| Dec 2019 | $3.68 M | - | - |
FAQ
- What is SAB Biotherapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for SAB Biotherapeutics?
- What is SAB Biotherapeutics annual CFF year-on-year change?
- What is SAB Biotherapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for SAB Biotherapeutics?
- What is SAB Biotherapeutics quarterly CFF year-on-year change?
- What is SAB Biotherapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for SAB Biotherapeutics?
- What is SAB Biotherapeutics TTM CFF year-on-year change?
What is SAB Biotherapeutics annual cash flow from financing activities?
The current annual CFF of SABS is $66.77 M
What is the all time high annual CFF for SAB Biotherapeutics?
SAB Biotherapeutics all-time high annual cash flow from financing activities is $66.77 M
What is SAB Biotherapeutics annual CFF year-on-year change?
Over the past year, SABS annual cash flow from financing activities has changed by +$65.72 M (+6250.88%)
What is SAB Biotherapeutics quarterly cash flow from financing activities?
The current quarterly CFF of SABS is -$674.10 K
What is the all time high quarterly CFF for SAB Biotherapeutics?
SAB Biotherapeutics all-time high quarterly cash flow from financing activities is $67.64 M
What is SAB Biotherapeutics quarterly CFF year-on-year change?
Over the past year, SABS quarterly cash flow from financing activities has changed by -$533.80 K (-380.47%)
What is SAB Biotherapeutics TTM cash flow from financing activities?
The current TTM CFF of SABS is $66.25 M
What is the all time high TTM CFF for SAB Biotherapeutics?
SAB Biotherapeutics all-time high TTM cash flow from financing activities is $66.78 M
What is SAB Biotherapeutics TTM CFF year-on-year change?
Over the past year, SABS TTM cash flow from financing activities has changed by +$58.72 M (+780.53%)